Log in

Alliance Pharma Stock Price, News & Analysis (LON:APH)

GBX 71.61
+0.61 (+0.86 %)
(As of 10/21/2019 06:34 AM ET)
Today's Range
71.20
Now: GBX 71.61
72.80
50-Day Range
65.90
MA: GBX 71.05
76.60
52-Week Range
59.20
Now: GBX 71.61
82.40
Volume77,939 shs
Average Volume488,126 shs
Market Capitalization£372.05 million
P/E Ratio17.47
Dividend Yield2.10%
BetaN/A
Alliance Pharma plc operates as a specialty pharmaceutical company in the United Kingdom, rest of Europe, and internationally. The company acquires, markets, and sells pharmaceutical products. It acquires the rights of established products, and owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The company also provides prescription only medicines, over the counter medications, cosmetics, and nutritional supplements, as well as medical devices. Read More…

Industry, Sector and Symbol

Industry Drugs - Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1249-466966

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£129.76 million
Cash FlowGBX 3.23 per share
Book ValueGBX 49.70 per share

Profitability

Miscellaneous

Employees200
Market Cap£372.05 million
Next Earnings DateN/A
OptionableOptionable

Receive APH News and Ratings via Email

Sign-up to receive the latest news and ratings for APH and its competitors with MarketBeat's FREE daily newsletter.


Alliance Pharma (LON:APH) Frequently Asked Questions

What is Alliance Pharma's stock symbol?

Alliance Pharma trades on the London Stock Exchange (LON) under the ticker symbol "APH."

How often does Alliance Pharma pay dividends? What is the dividend yield for Alliance Pharma?

Alliance Pharma declared a dividend on Tuesday, September 24th. Stockholders of record on Thursday, December 19th will be paid a dividend of GBX 0.54 per share on Friday, January 10th. This represents a dividend yield of 0.73%. The ex-dividend date is Thursday, December 19th. The official announcement can be viewed at this link. View Alliance Pharma's Dividend History.

What price target have analysts set for APH?

1 Wall Street analysts have issued 12-month price targets for Alliance Pharma's shares. Their forecasts range from GBX 115 to GBX 115. On average, they anticipate Alliance Pharma's stock price to reach GBX 115 in the next twelve months. This suggests a possible upside of 60.6% from the stock's current price. View Analyst Price Targets for Alliance Pharma.

What is the consensus analysts' recommendation for Alliance Pharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alliance Pharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alliance Pharma.

Has Alliance Pharma been receiving favorable news coverage?

Media stories about APH stock have trended somewhat positive on Monday, according to InfoTrie. The research firm rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Alliance Pharma earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Alliance Pharma.

Who are some of Alliance Pharma's key competitors?

What other stocks do shareholders of Alliance Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alliance Pharma investors own include RPC Group (RPC), Editas Medicine (EDIT), 1-800-Flowers.Com (FLWS), BlackBerry (BB), Direct Line Insurance Group (DLG), Telford Homes (TEF), XLMedia (XLM), Ally Financial (ALLY), Berry Global Group (BERY) and Air Canada (AC).

Who are Alliance Pharma's key executives?

Alliance Pharma's management team includes the folowing people:
  • Mr. Peter Jonathan Butterfield, CEO & Exec. Director (Age 43)
  • Mr. John Dawson, Founder & Non-Exec. Director (Age 70)
  • Mr. Andrew Timothy Franklin, CFO & Exec. Director (Age 53)
  • Mr. Stephen Kidner, Chief Scientific & Operations Officer
  • Mr. Daniel Thomas, Chief Corp. Devel. Officer

How do I buy shares of Alliance Pharma?

Shares of APH and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Alliance Pharma's stock price today?

One share of APH stock can currently be purchased for approximately GBX 71.61.

How big of a company is Alliance Pharma?

Alliance Pharma has a market capitalization of £372.05 million and generates £129.76 million in revenue each year. Alliance Pharma employs 200 workers across the globe.View Additional Information About Alliance Pharma.

What is Alliance Pharma's official website?

The official website for Alliance Pharma is http://www.alliancepharma.co.uk/.

How can I contact Alliance Pharma?

Alliance Pharma's mailing address is Avonbridge House, Bath Road, CHIPPENHAM, SN15 2BB, United Kingdom. The company can be reached via phone at +44-1249-466966.


MarketBeat Community Rating for Alliance Pharma (LON APH)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  185 (Vote Outperform)
Underperform Votes:  238 (Vote Underperform)
Total Votes:  423
MarketBeat's community ratings are surveys of what our community members think about Alliance Pharma and other stocks. Vote "Outperform" if you believe APH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel